FDA Grants Full Approval to Blinatumomab for MRD+ B-cell Precursor ALL

The FDA has granted regular approval to blinatumomab (Blincyto) for the treatment of adult and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease of at least 0.1%

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Germany ,Davidm Reese , ,Amgen ,Accessed June ,Blinatumomab ,Blincyto ,Nmrd ,Minimal Residual Disease ,B Cell Precursor Acute Lymphoblastic Leukemia ,Wall ,Leukemia ,Blood Cancer ,Fda ,Fda Approval ,Regular Approval ,Mlb All ,